GlassScriptPhysician profile
Heriberto Casanova
NPI 1275829459
$1,739.27
in general payments reported to CMS, 2019-2025
11 companies · $285 in 2025
The $285 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $98.82 · 2021: $99.12 · 2022: $193 · 2023: $378 · 2024: $311 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $461.37 | 2019-2025 | Interstim, Sonicision, Mahurkar |
| Janssen Pharmaceuticals, INC | $385.19 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $249.08 | 2022-2025 | Exalt Model D, Moses |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $200.17 | 2023-2025 | Lifevest |
| Johnson and Johnson International | $194.58 | 2019-2023 | Dermabond, Megadyne, Enseal X1 |
| Abbvie INC. | $108.68 | 2019-2023 | Vraylar |
| Stryker Corporation | $70.74 | 2022 | |
| Stemline Therapeutics INC. | $21.53 | 2024 | Orserdu |
| Merck Sharp & Dohme LLC | $19.54 | 2024 | Lynparza, Keytruda |
| Lilly USA, LLC | $15.23 | 2024 | Jardiance, Zepbound |
| Recordati_rare_diseases_inc. | $13.16 | 2024 | Signifor Lar, Isturisa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heriberto Casanova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.